The Indian pharmaceutical market ended December 2025 on a strong note.According to Pharmatrac data, total IPM value growth stood at a steady 10.6% for the month. Several large players showed double-digit growth — Torrent Pharma led with 17.2% growth, followed by Cipla at 15.5%, Sun Pharma at 15.2%, Lupin at 12.8%, and Zydus at 12.7%, while Dr Reddy’s grew 10.1% and Mankind Pharma posted 8.4% growth.
The anti-diabetic segment, which is now valued at ₹22,280 crore, grew 9.4% on a MAT basis as of December 2025, making it one of the fastest-growing large chronic therapy areas in the Indian pharma market.
And that context is important for the standout brand story of the month — Mounjaro.Read Also: Premier, Waaree Energies shares fall for third straight day, extend losses from post-listing peakMounjaro by Eli Lilly was ranked the number one brand in December 2025 based on monthly performance, underlining the pace at which it has scaled up in the Indian market. In fact, Mounjaro has been the fastest brand to rise to the top on a monthly value basis and has been the number one selling drug by value every month since October 2025, reflecting rapid adoption despite premium pricing.
The anti-diabetic segment, which is now valued at ₹22,280 crore, grew 9.4% on a MAT basis as of December 2025, making it one of the fastest-growing large chronic therapy areas in the Indian pharma market.
And that context is important for the standout brand story of the month — Mounjaro.Read Also: Premier, Waaree Energies shares fall for third straight day, extend losses from post-listing peakMounjaro by Eli Lilly was ranked the number one brand in December 2025 based on monthly performance, underlining the pace at which it has scaled up in the Indian market. In fact, Mounjaro has been the fastest brand to rise to the top on a monthly value basis and has been the number one selling drug by value every month since October 2025, reflecting rapid adoption despite premium pricing.
The anti-diabetic segment, which is now valued at ₹22,280 crore, grew 9.4% on a MAT basis as of December 2025, making it one of the fastest-growing large chronic therapy areas in the Indian pharma market.
- On an annualised basis, Mounjaro’s MAT sales as of December 2025 stood at ₹601 crore.
- MAT — or Moving Annual Total — represents total sales over the last 12 months.
- Other Diabetes drug Glycomet GP from USV clocked in ₹871 crore, ranked fourth in December and Mixtard from Abbott, a long-standing diabetes brand, logged ₹796 crore, ranking fifth for the month.
A quick look at the other Legacy brands in December
- Augmentin from GSK saw ₹889 crore in MAT sales, ranking number three in December.
- Foracort, a respiratory drug from Cipla, posted ₹828 crore, ranking second for the month.
- Pan from Alkem recorded ₹820 crore, ranking sixth in December.
The takeaway is clear: analysts say leadership is shifting, driven by new-age therapies like Mounjaro, even as established brands continue to dominate on a full-year basis. It’s a signal of how quickly India’s pharma market — especially diabetes and metabolic care — is evolving.
(Edited by : Juviraj Anchil)
